Drug intelligence / Profile preview

guacetisal

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

Guacetisal is a small molecule drug used primarily for the treatment of inflammatory diseases of the respiratory tract, such as chronic bronchitis and other airway conditions. Chemically, it is an ester formed from acetylsalicylic acid (aspirin) and guaiacol. Guacetisal exhibits anti-inflammatory, antitussive (cough-suppressing), expectorant (mucus-thinning), antipyretic (fever-reducing), and analgesic properties. It has been shown to be effective in both acute and chronic respiratory diseases by reducing inflammation and improving mucus clearance[1][3][4][6][8]. The drug was originally synthesized by Bayer Italia S.p.A.

Brand names: BroncaspinBalsacetilGuaiaspirProntomucil
Other names: Aspirin guaiacol esterO-Methoxyphenyl salicylate acetate

Targets

COX

Beyond the preview

Go deeper on guacetisal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on guacetisal.

Explore the full profile